Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro

Angiogenesis

Volumn 13, Issue 3, 2010, Pages 239-249

  Zahler, Stefan ^a   Liebl, Johanna ^a   Fürst, Robert ^a   Vollmar, Angelika M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

AKT; Cdk; Cyclin dependent kinase; ERK; GSK3 ; HUVEC

Indexed keywords

ALOISINE A; ALSTERPAULLONE; AMINOPURVALANOL; CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN 3' MONOXIME; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OLOMOUCINE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN KINASE P60; PROTEIN SERINE THREONINE KINASE INHIBITOR; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; APOPTOSIS; BETA CATENIN; BROMODEOXYURIDINE; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; ENDOTHELIAL CELLS; GENE SILENCING; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR MIMICRY; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES;

EID: 78149413177     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-010-9181-1     Document Type: Article

References (32)

1. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 932 936 1:CAS:528:DC%2BD2MXhtlSksrjF 10.1038/nature04478 16355210 (Pubitemid 43093958)
2. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 967 974 1:CAS:528:DC%2BD2MXhtlSksrnI 10.1038/nature04483 16355214 (Pubitemid 43093963)
3. AR Quesada MA Medina E Alba 2007 Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer Bioessays 29 1159 1168 1:CAS:528:DC%2BD2sXhtl2gtbfL 10.1002/bies.20655 17935210 (Pubitemid 350057387)
4. GR Zimmermann J Lehar CT Keith 2007 Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discov Today 12 34 42 1:CAS:528:DC%2BD2sXhsFOjsg%3D%3D 10.1016/j.drudis.2006.11.008 17198971 (Pubitemid 46014485)
5. J Bostrom SF Yu D Kan, et al. 2009 Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site Science 323 1610 1614 1:CAS:528:DC%2BD1MXjt1Cqurw%3D 10.1126/science.1165480 19299620
6. J Vesely L Havlicek M Strnad, et al. 1994 Inhibition of cyclin-dependent kinases by purine analogues Eur J Biochem 224 771 786 1:CAS:528: DyaK2cXmvFGktL0%3D 10.1111/j.1432-1033.1994.00771.x 7925396
7. M Knockaert P Greengard L Meijer 2002 Pharmacological inhibitors of cyclin-dependent kinases Trends Pharmacol Sci 23 417 425 1:CAS:528: DC%2BD38XntVWmsbY%3D 10.1016/S0165-6147(02)02071-0 12237154 (Pubitemid 35247771)
8. J Bain H McLauchlan M Elliott, et al. 2003 The specificities of protein kinase inhibitors: an update Biochem J 371 199 204 1:CAS:528: DC%2BD3sXitlCitrg%3D 10.1042/BJ20021535 12534346 (Pubitemid 36458094)
9. J Bain L Plater M Elliott, et al. 2007 The selectivity of protein kinase inhibitors: a further update Biochem J 408 297 315 1:CAS:528:DC%2BD2sXhtlGmtbjE 10.1042/BJ20070797 17850214
10. ZA Knight KM Shokat 2005 Features of selective kinase inhibitors Chem Biol 12 621 637 1:CAS:528:DC%2BD2MXlsFGhtrc%3D 10.1016/j.chembiol.2005.04.011 15975507 (Pubitemid 43142039)
11. L Meijer E Raymond 2003 Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials Acc Chem Res 36 417 425 1:CAS:528:DC%2BD3sXhs1Oksro%3D 10.1021/ar0201198 12809528
12. D Marko S Schatzle A Friedel, et al. 2001 Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells Br J Cancer 84 283 289 1:CAS:528:DC%2BD3MXht1Wgsrk%3D 10.1054/bjoc.2000.1546 11161389 (Pubitemid 32113458)
13. M Leost C Schultz A Link, et al. 2000 Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25 Eur J Biochem 267 5983 5994 1:CAS:528:DC%2BD3cXnt1Smtro%3D 10.1046/j.1432-1327.2000.01673.x 10998059
14. Y Mettey M Gompel V Thomas, et al. 2003 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects J Med Chem 46 222 236 1:CAS:528: DC%2BD38XpsFCnsLc%3D 10.1021/jm020319p 12519061 (Pubitemid 36078142)
15. S Bach M Knockaert J Reinhardt, et al. 2005 Roscovitine targets, protein kinases and pyridoxal kinase J Biol Chem 280 31208 31219 1:CAS:528: DC%2BD2MXpsVCmurY%3D 10.1074/jbc.M500806200 15975926 (Pubitemid 41291858)
16. M Knockaert N Gray E Damiens, et al. 2000 Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors Chem Biol 7 411 422 1:CAS:528:DC%2BD3cXktl2nsLc%3D 10.1016/S1074-5521(00)00124-1 10873834 (Pubitemid 30400044)
17. R Hoessel S Leclerc JA Endicott, et al. 1999 Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases Nat Cell Biol 1 60 67 1:CAS:528:DyaK1MXksVKitrk%3D 10.1038/9035 10559866
18. EW Ades FJ Candal RA Swerlick, et al. 1992 HMEC-1: establishment of an immortalized human microvascular endothelial cell line J Invest Dermatol 99 683 690 1:STN:280:DyaK3s7gslOnsw%3D%3D 10.1111/1523-1747.ep12613748 1361507
19. AS Rothmeier I Ischenko J Joore, et al. 2008 Investigation of the marine compound spongistatin 1 links the inhibition of PKC{alpha} translocation to nonmitotic effects of tubulin antagonism in angiogenesis FASEB J 23 1127 1137 10.1096/fj.08-117127 19056838
20. SB Blumenthal AK Kiemer G Tiegs, et al. 2005 Metalloporphyrins inactivate caspase-3 and -8 FASEB J 19 1272 1279 1:CAS:528:DC%2BD2MXnt1Oisbs%3D 10.1096/fj.04-3259com 16051694 (Pubitemid 41113724)
21. L Meijer AL Skaltsounis P Magiatis, et al. 2003 GSK-3-selective inhibitors derived from Tyrian purple indirubins Chem Biol 10 1255 1266 1:CAS:528:DC%2BD3sXhtVWis73O 10.1016/j.chembiol.2003.11.010 14700633 (Pubitemid 38050973)
22. M Knockaert P Lenormand N Gray, et al. 2002 p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol Oncogene 21 6413 6424 1:CAS:528:DC%2BD38XmvVOqtr8%3D 10.1038/sj.onc.1205908 12226745 (Pubitemid 35155446)
23. S Blagden BJ de 2005 Drugging cell cycle kinases in cancer therapy Curr Drug Targets 6 325 335 1:CAS:528:DC%2BD2MXktlansbg%3D 10.2174/1389450053765824 15857291 (Pubitemid 40667798)
24. TC Tran B Sneed J Haider, et al. 2007 Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish Cancer Res 67 11386 11392 1:CAS:528:DC%2BD2sXhtlyiu73L 10.1158/0008-5472.CAN-07-3126 18056466 (Pubitemid 350248566)
25. L Meijer A Borgne O Mulner, et al. 1997 Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 Eur J Biochem 243 527 536 1:CAS:528:DyaK2sXhtVWiu7g%3D 10.1111/j.1432-1033.1997.t01-2-00527.x 9030781
26. S Nam R Buettner J Turkson, et al. 2005 Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells Proc Natl Acad Sci USA 102 5998 6003 1:CAS:528:DC%2BD2MXkt1Cmu78%3D 10.1073/pnas.0409467102 15837920 (Pubitemid 40594244)
27. HS Kim C Skurk SR Thomas, et al. 2002 Regulation of angiogenesis by glycogen synthase kinase-3beta J Biol Chem 277 41888 41896 1:CAS:528: DC%2BD38XotF2gsbs%3D 10.1074/jbc.M206657200 12167628 (Pubitemid 35257501)
28. I Zachary 2003 VEGF signalling: integration and multi-tasking in endothelial cell biology Biochem Soc Trans 31 1171 1177 1:CAS:528: DC%2BD3sXps12jsrw%3D 10.1042/BST0311171 14641020
29. AW Orr JE Murphy-Ullrich 2004 Regulation of endothelial cell function BY FAK and PYK2 Front Biosci 9 1254 1266 1:CAS:528:DC%2BD2cXhtFGhtLw%3D 10.2741/1239 14977542
30. M Knockaert K Wieking S Schmitt, et al. 2002 Intracellular targets of Paullones. Identification following affinity purification on immobilized inhibitor J Biol Chem 277 25493 25501 1:CAS:528:DC%2BD38XlsVWhsL0%3D 10.1074/jbc.M202651200 11964410 (Pubitemid 34951864)
31. EW Newcomb 2004 Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity Anticancer Drugs 15 411 419 1:CAS:528:DC%2BD2cXktlWqtbc%3D 10.1097/01.cad.0000127332.06439.47 15166614 (Pubitemid 38736938)
32. RK Jain DG Duda JW Clark, et al. 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 24 40 1:CAS:528:DC%2BD28XhtVynsL0%3D 10.1038/ncponc0403 16407877 (Pubitemid 43108832)